Shattuck Labs, Inc. (NASDAQ:STTK) Sees Significant Increase in Short Interest

Shattuck Labs, Inc. (NASDAQ:STTK) saw a significant growth in short interest in January. As of January 15th, there was short interest totaling 2,198,677 shares, a growth of 113.8% from the December 31st total of 1,028,366 shares. Based on an average daily trading volume, of 791,757 shares, the days-to-cover ratio is currently 2.8 days. Approximately 3.9% of the shares of the company are sold short. Approximately 3.9% of the shares of the company are sold short. Based on an average daily trading volume, of 791,757 shares, the days-to-cover ratio is currently 2.8 days.

Wall Street Analysts Forecast Growth

STTK has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Shattuck Labs in a research report on Thursday, January 22nd. Citigroup lifted their price target on Shattuck Labs from $2.00 to $4.00 and gave the company a “neutral” rating in a research note on Tuesday, January 6th. Piper Sandler started coverage on shares of Shattuck Labs in a research report on Wednesday. They set an “overweight” rating and a $15.00 price objective for the company. Finally, HC Wainwright upgraded shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 price target for the company in a report on Monday, December 1st. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $6.20.

Shattuck Labs Stock Performance

Shares of NASDAQ STTK traded down $0.12 during midday trading on Friday, reaching $3.95. The stock had a trading volume of 55,682 shares, compared to its average volume of 872,154. Shattuck Labs has a twelve month low of $0.69 and a twelve month high of $4.89. The company’s 50 day moving average price is $3.49 and its 200 day moving average price is $2.23. The firm has a market cap of $249.96 million, a price-to-earnings ratio of -3.88 and a beta of 1.53.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. The firm had revenue of $1.00 million for the quarter. Equities analysts forecast that Shattuck Labs will post -1.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Shattuck Labs

Several institutional investors have recently bought and sold shares of STTK. Turtle Creek Wealth Advisors LLC bought a new stake in shares of Shattuck Labs in the 3rd quarter worth $29,000. Virtu Financial LLC purchased a new position in Shattuck Labs during the third quarter worth about $38,000. AQR Capital Management LLC grew its position in Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock worth $41,000 after purchasing an additional 31,355 shares in the last quarter. Qube Research & Technologies Ltd purchased a new stake in Shattuck Labs in the 2nd quarter valued at about $44,000. Finally, Squarepoint Ops LLC bought a new position in shares of Shattuck Labs during the 3rd quarter worth approximately $46,000. Institutional investors own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.